b-12

Wilmington, Delaware, United States

AI copilot platform for pharmaceutical and biotech companies that accelerates drug discovery by automating experimental planning and robotic execution.

Shareable draft

Check out b-12 on @MedStartr Today AI copilot platform for pharmaceutical and biotech companies that accelerates drug discovery by automating experimental planning and robotic execution. #MentalBehavioralHealth #DrugDiscoveryDevelopment #AIML #MedMo #MedStartrVentures

https://www.medstartr.ai/s/PzxodeIkg1Y

Get Involved in b-12

Problem Statement

Compresses early-stage drug discovery timelines from years to months.

Core Technology

AI copilot platform that converts natural language inputs into experimental designs and executable robotic instructions and interfaces with laboratory robots from Chemspeed, Opentrons, and Unchained in a vendor-agnostic manner.

Key Differentiators

Achieved 30x speed gains in experimental timelines with pilot programs; Eliminates typical 8-12 iteration cycles in chemical discovery workflows; Maintains vendor-agnostic integration with Chemspeed, Opentrons, and Unchained robotic platforms

Company Info

Business Model: B2B SaaS
Founded: 2025
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: b12-labs.com/

Disease Areas

Mental Health

Technologies

RoboticsAI & Machine Learning

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of b-12?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.